These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21394298)

  • 1. The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections.
    Lim SK; Lee SO; Choi SH; Choi JP; Kim SH; Jeong JY; Choi SH; Woo JH; Kim YS
    J Korean Med Sci; 2011 Mar; 26(3):325-31. PubMed ID: 21394298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. bloodstream infections: a multicenter retrospective analysis.
    Balkan II; Batirel A; Karabay O; Agalar C; Akalin S; Alici O; Alp E; Altay FA; Altin N; Arslan F; Aslan T; Bekiroglu N; Cesur S; Celik AD; Dogan M; Durdu B; Duygu F; Engin A; Engin DO; Gonen I; Guclu E; Guven T; Hatipoglu CA; Hosoglu S; Karahocagil MK; Kilic AU; Ormen B; Ozdemir D; Ozer S; Oztoprak N; Sezak N; Turhan V; Turker N; Yilmaz H
    Indian J Pharmacol; 2015; 47(1):95-100. PubMed ID: 25821319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicentre study of risk factors for mortality in patients with Acinetobacter bacteraemia receiving colistin treatment.
    Lee YT; Sun JR; Wang YC; Chiu CH; Kuo SC; Chen TL; ; Yang YS
    Int J Antimicrob Agents; 2020 Jun; 55(6):105956. PubMed ID: 32278810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Acute Kidney Injury and 28-Day Mortality in Carbapenem-Resistant
    Yu SN; Kim T; Park SY; Lee YM; Park KH; Lee EJ; Jeon MH; Choo EJ; Kim TH; Lee MS; Park SY
    Microb Drug Resist; 2021 Aug; 27(8):1029-1036. PubMed ID: 33656377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors and outcome for colistin-resistant Acinetobacter nosocomialis bacteraemia in patients without previous colistin exposure.
    Wang YC; Lee YT; Yang YS; Chen CT; Chiu CH; Yin T; Kuo SC; Chen TL; Lin JC; Wang FD; Fung CP; Chang FY
    Clin Microbiol Infect; 2015 Aug; 21(8):758-64. PubMed ID: 25980356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bloodstream infections caused by Acinetobacter species with reduced susceptibility to tigecycline: clinical features and risk factors.
    Park GE; Kang CI; Cha MK; Cho SY; Seok H; Lee JH; Kim JY; Ha YE; Chung DR; Peck KR; Lee NY; Song JH
    Int J Infect Dis; 2017 Sep; 62():26-31. PubMed ID: 28676346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia.
    Khawcharoenporn T; Pruetpongpun N; Tiamsak P; Rutchanawech S; Mundy LM; Apisarnthanarak A
    Int J Antimicrob Agents; 2014 Apr; 43(4):378-82. PubMed ID: 24613422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidrug resistant and extensively drug resistant Acinetobacter baumannii hospital infection associated with high mortality: a retrospective study in the pediatric intensive care unit.
    Shi J; Sun T; Cui Y; Wang C; Wang F; Zhou Y; Miao H; Shan Y; Zhang Y
    BMC Infect Dis; 2020 Aug; 20(1):597. PubMed ID: 32787942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors and clinical outcome of sulbactam nonsusceptibility in monomicrobial Acinetobacter nosocomialis bacteremia.
    Lai HH; Liou BH; Chang YY; Kuo SC; Lee YT; Chen TL; Fung CP
    J Microbiol Immunol Infect; 2016 Jun; 49(3):371-7. PubMed ID: 25081987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia.
    Liu CP; Shih SC; Wang NY; Wu AY; Sun FJ; Chow SF; Chen TL; Yan TR
    J Microbiol Immunol Infect; 2016 Dec; 49(6):934-940. PubMed ID: 25553994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance.
    Wareham DW; Bean DC; Khanna P; Hennessy EM; Krahe D; Ely A; Millar M
    Eur J Clin Microbiol Infect Dis; 2008 Jul; 27(7):607-12. PubMed ID: 18283503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcomes of patients with non-bacteremic pneumonia caused by extensively drug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex isolates: Is there any benefit of adding tigecycline to aerosolized colistimethate sodium?
    Jean SS; Hsieh TC; Lee WS; Hsueh PR; Hsu CW; Lam C
    Medicine (Baltimore); 2018 Sep; 97(39):e12278. PubMed ID: 30278498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 21st-century challenge to neurocritical care: the rise of the superbug Acinetobacter baumannii. A meta-analysis of the role of intrathecal or intraventricular antimicrobial therapy in reduction of mortality.
    Mohammed N; Savardekar AR; Patra DP; Narayan V; Nanda A
    Neurosurg Focus; 2017 Nov; 43(5):E8. PubMed ID: 29088961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colistin for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex.
    Zheng JY; Huang SS; Huang SH; Ye JJ
    J Microbiol Immunol Infect; 2020 Dec; 53(6):854-865. PubMed ID: 31607573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the effect of appropriate antimicrobial therapy on mortality associated with Acinetobacter nosocomialis bacteraemia.
    Kuo SC; Lee YT; Yang SP; Chiang MC; Lin YT; Tseng FC; Chen TL; Fung CP
    Clin Microbiol Infect; 2013 Jul; 19(7):634-9. PubMed ID: 22776466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Acinetobacter baumannii infection in critically ill surgical patients.
    Trottier V; Namias N; Pust DG; Nuwayhid Z; Manning R; Marttos AC; Dunham MB; Schulman CI; McKenney MG
    Surg Infect (Larchmt); 2007 Aug; 8(4):437-43. PubMed ID: 17883360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin.
    Michalopoulos A; Kasiakou SK; Rosmarakis ES; Falagas ME
    Scand J Infect Dis; 2005; 37(2):142-5. PubMed ID: 15764204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of parenteral colistin for the treatment of multiresistant Gram-negative organisms in major burn patients in South Korea.
    Cho YS; Yim H; Yang HT; Hur J; Chun W; Kim JH; Lee BC; Seo DK; Park JM; Kim D
    Infection; 2012 Feb; 40(1):27-33. PubMed ID: 21898119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrathecal colistin for drug-resistant Acinetobacter baumannii central nervous system infection: a case series and systematic review.
    Khawcharoenporn T; Apisarnthanarak A; Mundy LM
    Clin Microbiol Infect; 2010 Jul; 16(7):888-94. PubMed ID: 19686281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection.
    Lee YT; Kuo SC; Yang SP; Lin YT; Tseng FC; Chen TL; Fung CP
    Clin Infect Dis; 2012 Jul; 55(2):209-15. PubMed ID: 22495546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.